Search Results

Admedus Limited, announced that it has changed the Company’s name to Anteris Technologies Ltd. As of May 22, 2020 Anteris, is trading on the Australian Securities Exchange under the ticker AVR.

Admedus Limited (AHZ or the Company) announces the sale of its CardioCel® and VascuCel® patch business to U.S based LeMaitre Vascular Inc. (NASDAQ: LMAT, ‘LeMaitre’), for up to $A36.2M ($A22.8M upfront) in cash payments to Admedus.

LeMaitre Vascular, Inc., announced that it has acquired the biologic patch business of Admedus Ltd for $15.5 million, of which $14.2 million was paid at closing and $1.3 million is due in two post-closing installments, as well as potential earnout payments of $7.8 million payable based upon performance of the acquired business as well as other milestones.

From 30 January 2018, physicians in India will have access to the transformative power and significant patient benefits of ADAPT engineered tissue and Admedus’ flagship product CardioCel.

Admedus Ltd announces the publication of an independent study assessing the performance of CardioCel® in the prestigious peer-reviewed journal, The Annals of Thoracic Surgery.